Research programme: proto-oncogene protein c-met inhibitors - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 853474; MET inhibitors - Bayer HealthCare Pharmaceuticals

Latest Information Update: 29 Apr 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Bayer Schering Pharma
Developer Bayer HealthCare Pharmaceuticals
Class
Mechanism of Action Proto oncogene protein c met inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

16 Apr 2016 BAY 853474 is still in preclinical development for Cancer in Germany
01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
16 Nov 2010 Preclinical trials in Cancer in Germany (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.